Lataa...
Eradication of Factor VIII Inhibitors in Patients with Mild and Moderate Hemophilia A
In hemophilia A, up to 25% of new anti-factor VIII (FVIII) inhibitory antibodies (inhibitors) occur in patients with mild or moderate disease [1]. Once the inhibitor develops, options for management include observation, immune modulation, and immune tolerance induction (ITI). Currently, there is lit...
Tallennettuna:
| Päätekijät: | , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3645919/ https://ncbi.nlm.nih.gov/pubmed/22733686 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23269 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|